T
T-knife
Developing tumor-specific T cell receptor therapies for the treatment of cancer
About T-knife
T-knife is a biotechnology startup that operates in the healthcare sector, specifically in the development of innovative cancer treatments. The company's primary focus is on engineered T cell receptor therapies, also known as TCR-Ts. These therapies are designed to trigger a potent immune response to fight against solid tumors, a type of cancer that is often difficult to treat.
The company's unique selling proposition lies in its proprietary MyT platform. This platform is essentially a discovery engine that helps T-knife to identify new, tumor-specific human T cell receptors (TCRs). These TCRs are of high affinity and specificity, meaning they can bind strongly to cancer cells and are highly selective in their targets. This allows T-knife's therapies to target a wide range of cancer-related antigens, which are substances that can trigger an immune response.
T-knife's business model revolves around the development and commercialization of these TCR therapies. The company generates revenue by advancing its portfolio of TCR therapies through the various stages of clinical trials and eventually bringing them to market. Its clients are primarily patients with solid tumors who have limited treatment options.
In summary, T-knife is a promising startup in the biotech space, leveraging cutting-edge technology to develop novel cancer treatments. Its focus on TCR therapies could potentially revolutionize the treatment of solid tumors, providing hope for patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Berlin, Germany
- Employees
- 44
- Open positions
- 1
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, T Cell, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2021 | $110M | $440M | Casdin Capital · RA Capital Management · Andera Partners · Fidelity Investments | — |
| SERIES AOther financing | Aug 2020 | $73M | $290M | Versant Ventures · RA Capital Management | — |
Growth signals
Latest recorded traffic for T-knife is 80 monthly website visits, down 95.8% over the last three months. T-knife's team declined 26.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Versant Ventures
RA Capital Management
Fidelity Investments
Casdin Capital
Andera Partners
EQT Life Sciences
Qatar Investment Authority
Sixty Degree Capital
CaaS Capital Management
Other known investors4 additional known investors
Max Delbrück Center for Molecular Medicine
Charité Berlin University of Medicine
Free University of Berlin
Humboldt University of Berlin
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about T-knife on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See T-knife’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.